Functional Concept
Tenpoint Therapeutics Announces Breakthrough Phase 3 Results for Presbyopia Treatment Following Merger with Visus
Tenpoint Therapeutics, Visus merger, Phase 3 trial, presbyopia treatment, BRIMOCHOL PF, vision drug, ophthalmic therapeutics
Elinzanetant Shows Promise in Reducing Hot Flashes in Women Undergoing Breast Cancer Therapy
Elinzanetant, Vasomotor Symptoms, Breast Cancer, Adjuvant Endocrine Therapy, Hot Flashes, Non-Hormonal Treatment
Revival of Dormant Antipsychotic Class: LB Pharma’s Phase II Success with LB-102
LB Pharma, LB-102, Antipsychotic drugs, Schizophrenia treatment, Phase II clinical trials, Benzamide antipsychotics
LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial
LB-102, Benzamide antipsychotic, Schizophrenia treatment, Phase II clinical trial, PANSS score reduction, First-in-class potential
LB Pharma’s Novel Antipsychotic LB-102 Shows Promising Phase II Results for Schizophrenia
Schizophrenia treatment, Antipsychotic drugs, Clinical trial results, Benzamide class, LB-102
FDA Updates Label for Agios’ PYRUKYND with New Liver Injury Warning
Agios Pharmaceuticals, PYRUKYND, mitapivat, liver injury warning, FDA label update, thalassemia treatment
Metsera Advances with Positive Phase IIa Results for Monthly GLP-1RA Dosing
Metsera, GLP-1RA, MET-097i, obesity treatment, monthly dosing, weight loss, clinical trials
I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space
I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development
2024 FDA Drug Approvals: A Year of Strategic Approvals and Long-Awaited Treatments
FDA drug approvals 2024, novel drug approvals, accelerated approvals, cancer treatments, rare disease therapies
GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand
GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans